Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 study of livoletide (AZP-531) in Prader-Willi syndrome
2018-003062-13Phase 2Terminated
- Sponsor
- Millendo Therapeutics
- Start
- Nov 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Livoletide arm with Placebo arm (2 arms). Primary endpoints: Food-related behaviors (primary) and Safety and tolerability (primary). Started Nov 2018; status: terminated.
02
Drugs
livoletide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2018-003062-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003062-13.